Jan Trka
YOU?
Author Swipe
View article: HEPATITIS-ASSOCIATED VS IDIOPATHIC PAEDIATRIC APLASTIC ANAEMIA: CLONAL ARCHITECTURE AND DISEASE TRAJECTORY
HEPATITIS-ASSOCIATED VS IDIOPATHIC PAEDIATRIC APLASTIC ANAEMIA: CLONAL ARCHITECTURE AND DISEASE TRAJECTORY Open
View article: Tallforest: Multi-omic classifier for T-lineage acute lymphoblastic leukemia
Tallforest: Multi-omic classifier for T-lineage acute lymphoblastic leukemia Open
We previously demonstrated that T-lineage acute lymphoblastic leukemia (T-ALL) can be classified into 15 molecular subtypes based on whole transcriptome, exome, and genome sequencing (WTS/WGS)1. These subtypes are defined by distinct drive…
View article: Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia Open
View article: NGS‐MRD negativity in post‐HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk
NGS‐MRD negativity in post‐HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk Open
Monitoring of minimal residual disease (MRD) after hematopoietic stem cell transplantation (HSCT) in patients with acute lymphoblastic leukemia (ALL) is vital for timely therapeutic intervention planning. However, interpreting low‐positive…
View article: Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia
Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia Open
Not available.
View article: Somatic Mutations and Outcomes in CML Adolescent and Young Adults Compared to Children, Adults, and BCR::ABL1-positive ALL Patients
Somatic Mutations and Outcomes in CML Adolescent and Young Adults Compared to Children, Adults, and BCR::ABL1-positive ALL Patients Open
Adolescent and young adult (AYA) patients with chronic myeloid leukemia in chronic phase (CML-CP) reportedly fare worse on tyrosine kinase inhibitor (TKIs) than adults. This real-life study compared mutation profiles and outcomes in 80 AYA…
View article: PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome
PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome Open
View article: Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood—Are we there yet?
Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood—Are we there yet? Open
Can peripheral blood be used to detect residual disease in acute lymphoblastic leukaemia (ALL) when we increase the sensitivity of the method used? Bendig et al. found that a larger amount of material and the use of next‐generation sequenc…
View article: Data from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Data from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this …
View article: Supplementary Table S12 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S12 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Differentially expressed genes (adjusted P <0.01 ) in STAG2/LMO2 subtype compared to other T-ALL cases.
View article: Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Compounds used in single-dose (10uM) drug screening.
View article: Supplementary Table S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Detected mutations by whole genome or RNA sequencing.
View article: Supplementary Table S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Cox proportional hazards regression analysis of EFS and OS.
View article: Supplementary Table S14 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S14 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Up-regulated pathways in STAG2/LMO2 subtype compared to other T-ALL cases for mouse leukemia initiating cells (LIC) signatures analyzed by gene-set enrichment analysis (GSEA).
View article: Supplementary Table S24 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S24 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Lists of T-ALL related genes for filtering tumor-only and RNAseq samples.
View article: Supplementary Table S13 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S13 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Up-regulated pathways in STAG2/LMO2 subtype compared to other T-ALL cases analyzed by gene-set enrichment analysis (GSEA).
View article: Supplementary Table S11 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S11 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Patient characteristics of 24 cases of STAG2/LMO2 subtype T-ALL that were performed genomic analysis.
View article: Supplementary Table S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Differentially expressed genes (adjusted P <0.05) in three TLX3 subtypes (TLX3 γδ, TLX3 immature, TLX3 DP-like) compared to other T-ALL cases.
View article: Supplementary Table S7 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S7 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Detected structural variants by whole genome sequencing.
View article: Supplementary Table S25 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S25 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
CRISPR editing construct sequences.
View article: Supplementary Table S8 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S8 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Lists of feature genes for expression analysis.
View article: Supplementary Figure S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The genomic feature of LMO2 γδ-like T-ALL.
View article: Supplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The gene expression profiles of γδ T-ALL.
View article: Supplementary Figure S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Exploration of targets in STAG2/LMO2 T-ALL.
View article: Supplementary Table S22 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S22 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The results of dose-response validation for 138 compounds.
View article: Supplementary Table S9 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S9 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Differentially expressed genes (adjusted P <0.01 ) of LMO2 γδ-like subtype vs other T-ALL.
View article: Supplementary Figure S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The feature gene expression of STAG2/LMO2 subtype T-ALL.
View article: Supplementary Table S18 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S18 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Common differentially expressed genes (adjusted P <0.01 ) in PF382-STAG2KO v. PF382-WT model and primary samples with STAG2/LMO2 v. other subtypes.
View article: Supplementary Figure S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The clinical features of γδ T-ALL.
View article: Supplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Differentially expressed genes (adjusted P <0.01 ) between PF382-STAG2KO and PF382-WT.